CEO, TARSUS PHARMACEUTICALS
WHY: Runs clinical-stage drugmaker with nearly $400M valuation. Went public in October. Counts positions with leading healthcare venture capital firm Versant Ventures and chief executive roles at device makers Metavention and Vibrato Medical. Harvard Medical School alumnus.
RECENT: IPO plans filed in September; raised over $100M in proceeds to finance drug development for inflammatory eye condition, dry eye syndrome, more.
NOTABLE: Tarsus backers include Newport Beach’s Flying L Partners and Horowitz Group, and Aliso Viejo-based Visionary Ventures, an offshoot of business accelerator Octane.
2020 HOBBY: “Snorkeling the coves of CDM and Laguna —a happy and reflective place observing the beauty hidden around us.”